SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

OCS starts PIONEER-1 trial after first Privosegtor patient treated

OCS says it has treated the first patient in its PIONEER-1 registrational trial of Privosegtor for optic neuritis.

OCS

This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.